A multicenter retrospective study was designed to assess clinical outcome of COVID-19 in patients with hematological malignancies (HM) following treatment with anti-SARS-CoV-2 convalescent plasma (CP) or standard of care therapy. To this aim, a propensity score matching was used to assess the role of non-randomized administration of CP in this high-risk cohort of patients from the Italian Hematology Alliance on COVID-19 (ITA-HEMA-COV) project, now including 2049 untreated control patients. We investigated 30- and 90-day mortality, rate of admission to intensive care unit, proportion of patients requiring mechanical ventilatory support, hospitalization time, and SARS-CoV-2 clearance in 79 CP recipients and compared results with 158 propensity score-matched controls. Results indicated a lack of efficacy of CP in the study group compared with the untreated group, thus confirming the negative results obtained from randomized studies in immunocompetent individuals with COVID-19. In conclusion, this retrospective analysis did not meet the primary and secondary end points in any category of immunocompromized patients affected by HM.

Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study / F. Lanza, F. Ciceri, R. Cairoli, M.V. Sacchi, A. Guidetti, M. Marchetti, M. Massaia, L. Arcaini, M. Krampera, S. Mohamed, F. Gherlinzoni, C. Mecucci, M. Gentile, I. Romano, A. Venditti, M. Ruggeri, D. Ferrero, E. Coviello, E. Fabbri, P. Corradini, F. Passamonti, F. Monaco. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 1099-1069. - 40:5(2022 Dec), pp. 857-863. [10.1002/hon.3060]

Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study

A. Guidetti;P. Corradini;
2022

Abstract

A multicenter retrospective study was designed to assess clinical outcome of COVID-19 in patients with hematological malignancies (HM) following treatment with anti-SARS-CoV-2 convalescent plasma (CP) or standard of care therapy. To this aim, a propensity score matching was used to assess the role of non-randomized administration of CP in this high-risk cohort of patients from the Italian Hematology Alliance on COVID-19 (ITA-HEMA-COV) project, now including 2049 untreated control patients. We investigated 30- and 90-day mortality, rate of admission to intensive care unit, proportion of patients requiring mechanical ventilatory support, hospitalization time, and SARS-CoV-2 clearance in 79 CP recipients and compared results with 158 propensity score-matched controls. Results indicated a lack of efficacy of CP in the study group compared with the untreated group, thus confirming the negative results obtained from randomized studies in immunocompetent individuals with COVID-19. In conclusion, this retrospective analysis did not meet the primary and secondary end points in any category of immunocompromized patients affected by HM.
COVID-19; convalescent plasma; disease severity; hematological malignancy; survival data;
Settore MED/15 - Malattie del Sangue
6-ago-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
Hematological Oncology - 2022 - Lanza - Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 235.09 kB
Formato Adobe PDF
235.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/940501
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact